Pamela Vig Sells 30,559 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insider Pamela Vig sold 30,559 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $34.00, for a total transaction of $1,039,006.00. Following the sale, the insider now directly owns 27,406 shares of the company’s stock, valued at approximately $931,804. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock opened at $33.11 on Friday. The company has a current ratio of 3.68, a quick ratio of 3.47 and a debt-to-equity ratio of 1.31. The company has a market cap of $1.56 billion, a PE ratio of -8.92 and a beta of 1.10. The company has a 50 day moving average of $26.23 and a 200-day moving average of $27.26. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $35.56.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, May 8th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.14). The business had revenue of $69.22 million for the quarter, compared to the consensus estimate of $69.71 million. Mirum Pharmaceuticals had a negative return on equity of 56.46% and a negative net margin of 69.67%. As a group, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on MIRM. Baird R W upgraded Mirum Pharmaceuticals to a “strong-buy” rating in a report on Monday, June 17th. Stifel Nicolaus restated a “buy” rating and issued a $48.00 price target on shares of Mirum Pharmaceuticals in a research note on Monday, June 17th. SVB Leerink lowered their price objective on Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a research report on Monday, March 18th. Morgan Stanley boosted their target price on shares of Mirum Pharmaceuticals from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Tuesday, June 18th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $40.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, May 9th. Ten analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $53.64.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Swiss National Bank increased its position in Mirum Pharmaceuticals by 1.3% during the 3rd quarter. Swiss National Bank now owns 54,400 shares of the company’s stock worth $1,719,000 after purchasing an additional 700 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Mirum Pharmaceuticals by 210.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 224,571 shares of the company’s stock valued at $7,096,000 after acquiring an additional 152,287 shares during the last quarter. Federated Hermes Inc. boosted its holdings in shares of Mirum Pharmaceuticals by 71.2% during the 3rd quarter. Federated Hermes Inc. now owns 20,544 shares of the company’s stock valued at $649,000 after acquiring an additional 8,544 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in Mirum Pharmaceuticals by 202.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 114,109 shares of the company’s stock worth $3,606,000 after acquiring an additional 76,369 shares during the last quarter. Finally, Profund Advisors LLC increased its holdings in Mirum Pharmaceuticals by 9.2% in the 3rd quarter. Profund Advisors LLC now owns 23,056 shares of the company’s stock worth $729,000 after purchasing an additional 1,940 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.